Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.89, while Novo Nordisk A/S trades at $44.69 (market cap $200.69B). The key difference: Novo Nordisk A/S pays a 3.98% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $81.00 | $63.98 |
52-Week Low | $11.55 | $35.29 |
Market Cap | — | $200.69B |
Enterprise Value | — | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.49, down 3.55% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, with recent payouts ranging from $0.15 to $0.28. News coverage highlights high distribution yields but also significant NAV erosion, with some sources reporting a 67.45% decline over the past year. Support and resistance are tightly clustered around $15-$16, indicating limited near-term price movement.
The outlook is mixed: high income potential from distributions appeals to yield-seeking investors, but structural risks and capital depreciation pose substantial downside. Investors face uncapped losses despite weekly payouts, with fees and tax implications further eroding returns. Careful risk assessment is essential given the fund's volatility and performance history.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
